Victory Pharma (Victory) has reported that the US Food and Drug Administration (FDA) has accepted the company’ New Drug Application (NDA) for MGX006, for review.
The company said that, if approved, MGX006 is expected to provide patients and healthcare providers the advantage of an antiemetic agent combined with a proprietary formulation, ideally suited for the treatment of nausea and vomiting.
Matt Heck, CEO of Victory, said: “Pending FDA approval, we are planning for a first half of 2010 product launch, allowing Victory to further leverage its 150 person field sales organization. Given many patients suffering from pain also suffer from emesis, there is a good fit between MGX006 and Victory’s growing, pain management franchise.